IL1B and metabolic dysfunction-associated steatohepatitis: Moreover, luteolin can mitigate NASH, a stage of MAFLD, by targeting the pro-inflammatory IL-1 and IL-18 pathways.[68] All these facts indicate that luteolin could be a target drug compound for MAFLD and COVID-19 comorbidity patients.